Corimmun Exit
Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.
Exit since June 2012.
MYR Exit
MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.
Sector: Pharmaceuticals
Website:
myr-pharma.com
HTGF-Manager: Dr. Bernd Goergen
In portfolio 21. Jan 2011 – 09. Dec 2020
Provecs Medical Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system.
Exit since July 2015.
